Top Medical Searches

Current Medical News

‘We will never forget him’: Trump addresses widow of slain SEAL as doubts linger over mission

‘We will never forget him’: Trump addresses widow of slain SEAL as doubts linger over missionAs debate continues to swirl over the mission’s results, President Trump’s acknowledgment of a fallen soldier’s wife was the most emotional moment of his first congressional address. Carryn Owens, whose husband, Navy SEAL William “Ryan” Owens, was killed in a Yemen raid last month, was moved to tears as Trump praised her husband’s sacrifice. “Ryan died as he lived,” said Trump.

Read More..

February 28th, 2017

Reject 'Ryancare,' Wife Of Freedom Caucus Leader Urges

Reject 'Ryancare,' Wife Of Freedom Caucus Leader UrgesRep. Mark Meadows said he was unaware his wife had sent a letter urging complete repeal of the Affordable Care Act.

Read More..

February 28th, 2017

Accera’s Alzheimer’s trial fails, in yet another setback for disease

(Reuters) – Nestle SA-backed Accera Inc said on Tuesday its experimental Alzheimer’s drug failed a late-stage study, adding to the laundry list of disappointments in the pursuit of an effective treatment for the rampant mind-wasting disease.

 Read more…

February 28th, 2017

India issues fresh antibiotic guidelines to tackle superbug menace

MUMBAI (Thomson Reuters Foundation) – India, one of the world’s biggest consumers of antibiotics, has issued new national guidelines on their use as part of a drive to fight the rise of drug-resistant superbugs.

 Read more…

February 28th, 2017

FDA Approves Xermelo (telotristat ethyl) as First and Only Oral Treatment for Carcinoid Syndrome Diarrhea in Cancer Patients with Metastatic Neuroendocrine Tumors

The Woodlands, Texas, February 28, 2017 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that the U.S. Food and Drug Administration (FDA) has approved Xermelo (telotristat ethyl) 250 mg as a first and only orally administered therapy… Read More..

February 28th, 2017
Copyright 2008 © Drugs and Diseases. Developed by Axilosoft
Home | About Us | Privacy Policy | Contact Us